274 related articles for article (PubMed ID: 18818197)
41. Spirooxindoles as novel 3D-fragment scaffolds: Synthesis and screening against CYP121 from M. tuberculosis.
Davis HJ; Kavanagh ME; Balan T; Abell C; Coyne AG
Bioorg Med Chem Lett; 2016 Aug; 26(15):3735-40. PubMed ID: 27287372
[TBL] [Abstract][Full Text] [Related]
42. Oxygen activation and electron transfer in flavocytochrome P450 BM3.
Ost TW; Clark J; Mowat CG; Miles CS; Walkinshaw MD; Reid GA; Chapman SK; Daff S
J Am Chem Soc; 2003 Dec; 125(49):15010-20. PubMed ID: 14653735
[TBL] [Abstract][Full Text] [Related]
43. High-throughput virtual screening, ADME analysis, and estimation of MM/GBSA binding-free energies of azoles as potential inhibitors of
Madhavaram M; Nampally V; Gangadhari S; Palnati MK; Tigulla P
J Recept Signal Transduct Res; 2019 Aug; 39(4):312-320. PubMed ID: 31658859
[TBL] [Abstract][Full Text] [Related]
44. Structure, function and drug targeting in Mycobacterium tuberculosis cytochrome P450 systems.
McLean KJ; Dunford AJ; Neeli R; Driscoll MD; Munro AW
Arch Biochem Biophys; 2007 Aug; 464(2):228-40. PubMed ID: 17482138
[TBL] [Abstract][Full Text] [Related]
45. Overcoming the limitations of fragment merging: rescuing a strained merged fragment series targeting Mycobacterium tuberculosis CYP121.
Hudson SA; Surade S; Coyne AG; McLean KJ; Leys D; Munro AW; Abell C
ChemMedChem; 2013 Sep; 8(9):1451-6. PubMed ID: 23788280
[No Abstract] [Full Text] [Related]
46. Structure-based discovery of novel inhibitors of Mycobacterium tuberculosis CYP121 from Indonesian natural products.
Prasasty VD; Cindana S; Ivan FX; Zahroh H; Sinaga E
Comput Biol Chem; 2020 Apr; 85():107205. PubMed ID: 31981965
[TBL] [Abstract][Full Text] [Related]
47. A three-dimensional model of lanosterol 14alpha-demethylase of Candida albicans and its interaction with azole antifungals.
Ji H; Zhang W; Zhou Y; Zhang M; Zhu J; Song Y; Lü J
J Med Chem; 2000 Jun; 43(13):2493-505. PubMed ID: 10891108
[TBL] [Abstract][Full Text] [Related]
48. Design, synthesis and evaluation against Mycobacterium tuberculosis of azole piperazine derivatives as dicyclotyrosine (cYY) mimics.
El-Wahab HAAA; Accietto M; Marino LB; McLean KJ; Levy CW; Abdel-Rahman HM; El-Gendy MA; Munro AW; Aboraia AS; Simons C
Bioorg Med Chem; 2018 Jan; 26(1):161-176. PubMed ID: 29183661
[TBL] [Abstract][Full Text] [Related]
49. Structural characterization of CYP144A1 - a cytochrome P450 enzyme expressed from alternative transcripts in Mycobacterium tuberculosis.
Chenge J; Kavanagh ME; Driscoll MD; McLean KJ; Young DB; Cortes T; Matak-Vinkovic D; Levy CW; Rigby SE; Leys D; Abell C; Munro AW
Sci Rep; 2016 May; 6():26628. PubMed ID: 27225995
[TBL] [Abstract][Full Text] [Related]
50. Multiple drug binding modes in Mycobacterium tuberculosis CYP51B1.
Lockart MM; Butler JT; Mize CJ; Fair MN; Cruce AA; Conner KP; Atkins WM; Bowman MK
J Inorg Biochem; 2020 Apr; 205():110994. PubMed ID: 31982812
[TBL] [Abstract][Full Text] [Related]
51. Exploring Covalent Allosteric Inhibition of Antigen 85C from Mycobacterium tuberculosis by Ebselen Derivatives.
Goins CM; Dajnowicz S; Thanna S; Sucheck SJ; Parks JM; Ronning DR
ACS Infect Dis; 2017 May; 3(5):378-387. PubMed ID: 28285521
[TBL] [Abstract][Full Text] [Related]
52. An enlarged, adaptable active site in CYP164 family P450 enzymes, the sole P450 in Mycobacterium leprae.
Agnew CR; Warrilow AG; Burton NM; Lamb DC; Kelly SL; Brady RL
Antimicrob Agents Chemother; 2012 Jan; 56(1):391-402. PubMed ID: 22037849
[TBL] [Abstract][Full Text] [Related]
53. Application of fragment screening and merging to the discovery of inhibitors of the Mycobacterium tuberculosis cytochrome P450 CYP121.
Hudson SA; McLean KJ; Surade S; Yang YQ; Leys D; Ciulli A; Munro AW; Abell C
Angew Chem Int Ed Engl; 2012 Sep; 51(37):9311-6. PubMed ID: 22890978
[No Abstract] [Full Text] [Related]
54. Structural and spectroscopic analysis of the F393H mutant of flavocytochrome P450 BM3.
Ost TW; Munro AW; Mowat CG; Taylor PR; Pesseguiero A; Fulco AJ; Cho AK; Cheesman MA; Walkinshaw MD; Chapman SK
Biochemistry; 2001 Nov; 40(45):13430-8. PubMed ID: 11695889
[TBL] [Abstract][Full Text] [Related]
55. Reverse type I inhibitor of Mycobacterium tuberculosis CYP125A1.
Ouellet H; Kells PM; Ortiz de Montellano PR; Podust LM
Bioorg Med Chem Lett; 2011 Jan; 21(1):332-7. PubMed ID: 21109436
[TBL] [Abstract][Full Text] [Related]
56. Structural basis of steroid binding and oxidation by the cytochrome P450 CYP109E1 from Bacillus megaterium.
Jóźwik IK; Kiss FM; Gricman Ł; Abdulmughni A; Brill E; Zapp J; Pleiss J; Bernhardt R; Thunnissen AW
FEBS J; 2016 Nov; 283(22):4128-4148. PubMed ID: 27686671
[TBL] [Abstract][Full Text] [Related]
57. Engineering a self-sufficient Mycobacterium tuberculosis CYP130 by gene fusion with the reductase-domain of CYP102A1 from Bacillus megaterium.
Ortega Ugalde S; Luirink RA; Geerke DP; Vermeulen NPE; Bitter W; Commandeur JNM
J Inorg Biochem; 2018 Mar; 180():47-53. PubMed ID: 29232638
[TBL] [Abstract][Full Text] [Related]
58. A single mutation in cytochrome P450 BM3 induces the conformational rearrangement seen upon substrate binding in the wild-type enzyme.
Joyce MG; Girvan HM; Munro AW; Leys D
J Biol Chem; 2004 May; 279(22):23287-93. PubMed ID: 15020590
[TBL] [Abstract][Full Text] [Related]
59. Insights into regioselective metabolism of mefenamic acid by cytochrome P450 BM3 mutants through crystallography, docking, molecular dynamics, and free energy calculations.
Capoferri L; Leth R; ter Haar E; Mohanty AK; Grootenhuis PD; Vottero E; Commandeur JN; Vermeulen NP; Jørgensen FS; Olsen L; Geerke DP
Proteins; 2016 Mar; 84(3):383-96. PubMed ID: 26757175
[TBL] [Abstract][Full Text] [Related]
60. Conservation in the CYP51 family. Role of the B' helix/BC loop and helices F and G in enzymatic function.
Lepesheva GI; Virus C; Waterman MR
Biochemistry; 2003 Aug; 42(30):9091-101. PubMed ID: 12885242
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
